MRX-6313

N/A

Report date: 2022/08/24 20:00:31
NME

Base Information

Drug NameMRX-6313
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsReceptor protein-tyrosine kinase inhibitors
TargetsTyrosine-protein kinase receptor FLT3Receptor protein-tyrosine kinase
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of North Carolina At Chapel Hill
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMeryx Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A